The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy

Cardiovascular Research

Volumn 45, Issue 1, 2000, Pages 82-91

  Van Zwieten, P A ^a  

^a Cardiol Cardiopulmonary Surg A   (Netherlands)

Author keywords

Antihypertensive agents; Heart rate (variability); Hemodynamics; Hypertension; Hypertrophy; Ventricular function

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUNAZOSIN; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE; IRBESARTAN; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; MINOXIDIL; MOXONIDINE; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; QUINAPRIL; RESERPINE; RILMENIDINE; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; VASODILATOR AGENT; VERAPAMIL;

ADRENERGIC SYSTEM; ANIMAL MODEL; BLOOD PRESSURE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 0033991103     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00291-6     Document Type: Review

References (80)

1. Savage D.D., Garrison R.J., Kannel W.B., et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation. 75:(suppl.I):1987;I26-I33.
2. Pegram B.L., Ishise S., Frohlich E.D. Effect of methyldopa, clonidine and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats. Cardiovasc Res. 16:1982;40-46.
3. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. New Engl J Med. 327:1992;998-1008.
4. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol. 19:1992;1550-1558.
5. Pluim B.M., Vliegen H.W., van der Laarse A., van der Wall E.E. Pathological left ventricular hypertrophy. Cardiologie. 5:1998;574-582.
6. Spirito P., Pelliccia A., Proschan M.A., et al. Morphology of the 'athlete's heart' assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol. 74:1994;802-806.
7. Koffland M.J.M., van der Lee C., ten Cate F.J., Roelandt J.R.T.C. Hypertrophic cardiomyopathy: update and new perspectives. Cardiologie. 5:1998;511-524.
8. Weber K.T., Sun Y., Guarda E. Structural remodelling in hypertensive heart disease and the role of hormones. Hypertension. 23:1994;869-877.
9. Sen S., Tarazi R.C., Khairalla P.A., Bumpus F.M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 35:1974;775-781.
10. Frohlich E.D., Tarazi R.C. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol. 44:1979;959-963.
11. Friberg P., Nordlander M. Influence of left ventricular and coronary vascular hypertrophy on cardiac performance. J Hypertens. 8:1990;879-889.
12. Owens G.K., Reidy M.A. Hyperplastic growth response of vascular smooth muscle following induction of acute hypertension in rats by aortic coarctation. Circ Res. 57:1985;695-705.
13. Gwathmey J.K., Morgan J.P. Altered calcium handling in experimental pressure overload hypertrophy in the ferret. Circ Res. 57:1985;836-843.
14. Newling R.P., Fletcher P.J., Conts M., Shaw J. Noradrenaline and cardiac hypertrophy in the rat: changes in morphology, blood pressure, and ventricular performance. J Hypertens. 7:1989;561-567.
15. Jeppson A.B., Waldeck B., Widmark E. Further studies on the cardiomegaly induced by β-adrenoceptor agonists. Acta Pharmacol Toxicol. 58:1986;121-125.
16. Spinale F.G., Holzgrefe H., Mukherjee R., et al. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction. J Pharm Exp Ther. 283:1997;1082-1094.
17. Nakamura F., Nagano M., Kobayshi R., et al. Chronic administration of angiotensin II-receptor antagonist, TCV 116, in cardiomyopathic hamsters. Am J Physiol. 267:1994;H2297-2304.
18. Brown L., Miller J., Dagger A., Sernia C. Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol. 31:1998;108-115.
19. Struijker Boudier H.A.J., Smits J.F.M., De Mey J.G.R. Pharmacology of cardiovascular remodelling. Annu Rev Pharmacol Toxicol. 35:1995;509-539.
20. Mertens M.J.F., Pfaffendorf M., van Zwieten P.A. Impaired inotropic responses in hypertension-induced cardiac hypertrophy. High Blood Press. 2:1993;195-205.
21. Mertens M.J.F., Batink H.D., Pfaffendorf M., van Zwieten P.A. Depressed inotropic response to beta-adrenoceptor agonists in the presence of advanced cardiac hypertrophy in hearts from rats with induced aortic stenosis and from spontaneously hypertensive rats. J Hypertens. 10:1992;1361-1368.
22. 1- but not to β-adrenoceptor stimulation in isolated hearts from spontaneously hypertensive rats. J Hypertens. 10:1992;143-148.
23. Castellano M., Böhm D., Agabiti Rosei E. Adrenergic receptors in hypertensive heart disease. High Blood Press. 5:1996;178-180.
24. Van Bilsen M., Doevendans P.A.F.M., Reneman R.S., van er Vusse G.J. Metabolic remodelling of the hypertrophied and failing heart. Cardiologie. 5:1998;727-733.
25. Kulbertus H.E. Electrocardiographic aspects of left ventricular hypertrophy. ter Keurs H., Schipperheijn J. Cardiac left ventricular hypertrophy. 1983;197-207 Martinus Nijhoff, Den Haag.
26. Allison J.D., Flickinger F.W., Wright J.C., et al. Measurement of left ventricular mass in hypertrophic cardiomyopathy using MRI: comparison with echocardiography. Magn Reson Imaging. 11:1993;329-334.
27. Sayad D.E., Clarke G.D., Peshock R.M. Magnetic resonance imaging of the heart and its role in current cardiology. Curr Opin Cardiol. 10:1995;640-649.
28. Van Zwieten P.A. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens. 15:(suppl.1):1997;S3-S8.
29. Amann K., Greber D., Gharehbagi H., et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Am J Hypertens. 5:1992;76-83.
30. Callens-El Amrani F., Paologgi F., Swynghedauw B. Remodelling of the heart in DOCA-salt hypertensive rats by propranolol and by an alpha-2 agonist, rilmenidine. J Hypertens. 7:1989;947-954.
31. Rossi M.A., Carillo S.V. Does norepinephrine play a central causative role in the process of cardiac hypertrophy? Am Heart J. 106:1985;622-623.
32. Friberg P., Folkow B., Nordlander M. Cardiac dimensions in spontaneously hypertensive rats following different modes of blood pressure reduction by antihypertensive treatment. J Hypertens. 4:1986;85-92.
33. Dellsperger K., Martins J.B., Clothier J.L., Marcus M.L. Incidence of sudden cardiac death associated with coronary occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by β-adrenergic blockade. Circulation. 82:1990;941-950.
34. Castellano M., Böhm M. The cardiac β-adrenoceptor mediated signalling pathway and its alterations in hypertensive heart disease. Hypertension. 29:1997;715-722.
35. 1-adrenergic antagonist bunazosin in Dahl-sensitive rats. Hypertens Res. 19:1996;147-150.
36. Jespersen L.T., Nyborg N.C.B., Lederballe Pedersen O., et al. Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension. 7:1985;734-741.
37. Zolk O., Flesch M., Schnabel P., et al. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector. Mechanisms in transgenic (m REN 2) 27 rats. Br J Pharmacol. 123:1998;405-412.
38. Tsoporis J., Leenen F.H. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension. 11:1988;376-386.
39. Leenen F.H., Prowse S. Time course of changes in cardiac hypertrophy and pressor mechanisms in two-kidney, one clip hypertensive rats during treatment with minoxidil, enalapril or after uniphrectomy. J Hypertens. 5:1987;73-83.
40. Kim S., Hamaguchi A., Shinkawa T., et al. Molecular effects of M17055, furosemide and thiazide on cardiac hypertrophy of spontaneously hypertensive rats. J Pharmacol Exp Ther. 279:1996;983-990.
41. Renney D.G., Robinson M.C. Effects of verapamil and carbon monoxide on blood pressure and heart mass in the spontaneously hypertensive rat. Eur J Pharmacol. 182:1990;29-36.
42. Motz W., Strauer B.E. Regression of cardiac hypertrophy after therapy in animal hypertension. J Cardiovasc Pharmacol. 7:1985;S56-S61.
43. Watanabe M., Kawaghuci H., Onozuka H., et al. Chronic effects of enalapril and amlodipine on cardiac remodelling in cardiomyopathic hamster hearts. J Cardiovasc Pharmacol. 32:1998;248-259.
44. Balke C.W., Shorofsky S. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res. 37:1998;290-299.
45. Nunez E., Hosoya K., Susic D., Frohlich D. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 29:(part 2):1997;519-524.
46. Ennis I.L., Alvarez B.V., Camilión de Hurtado M.C., Cingolani H.E. Enalapril induces regression of cardiac hypertrophy and normalisation of pH; regulatory mechanisms. Hypertension. 31:1998;961-967.
47. Clozel J.P., Hefti F. Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 11:1988;568-572.
48. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Hypertension. 28:1996;269-275.
49. Harrap S.B., O'Sullivan J.B. Cardiac transplantation, perindopril, and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertension. 28:1996;622-626.
50. Nagano M., Higaki J., Mikami H., et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 9:1991;595-599.
51. Mukawa H., Toki Y., Shimanchi A., et al. Pressure overload per se rather than cardiac angiotensin converting enzyme may be important in the development of rat cardiac hypertrophy. J Hypertens. 15:1997;1027-1032.
52. Spinale F.G., Holzgrefe H.H., Walker J.D., et al. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: the effects on ventricular and myocyte function. J Cardiovasc Pharmacol. 30:1997;623-631.
53. 1-receptor inhibition. Circulation. 95:1997;1592-1600.
54. Sabri A., Samuel J.L., Marotte F., et al. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension. 32:1998;371-375.
55. Lanza G.M., Scott M.J., Davison G., et al. Angiotensin II-receptor blockade in Syrian Hamster (To-2) cardiomyopathy does not affect microscopic cardiac material properties: implications for mechanisms of tissue remodelling. Cardiovasc Drugs Ther. 11:1997;521-529.
56. Fraccarollo D., Hu K., Galuppo P., et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilatation and improves cardiac function in rats with myocardial infarction. Circulation. 96:1997;3963-3973.
57. Liebson P.R., Grandits G.A., Dianzumba S., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 91:1995;698-706.
58. Gosse P., Roudant R., Herrero G. Dallochio M. β-Blockers vs. angiotensin converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol. 16:(suppl.5):1990;S145-S150.
59. Margaroli P., Petrucci E., Caielli R., et al. Non-invasive assessment of left ventricular anatomy and function in hypertensive patients following successful treatment of hypertension with the beta-adrenergic blocking drug atenolol. Acta Ther. 11:1985;5-12.
60. Cifkovà R., Niederle P., Romanovskà L., et al. Heart and vessel hypertrophy in hypertension: possibilities of regression. J Hypertens. 5:(suppl.5):1987;S407-S410.
61. Strauer B.E., Bayer F., Brecht H.M., Motz W. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens. 3:(suppl.4):1985;S39-S44.
62. Eichstädt H., Richter W., Bäder W., et al. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther. 3:1989;583-587.
63. Agabiti-Rosei E., Muiesan M.L., Rizzoni D., et al. Regression of cardiovascular structural changes after long-term antihypertensive treatment with the calcium antagonist nitrendipine. J Cardiovasc Pharmacol. 18:(suppl.5):1991;S5-S9.
64. Gerritsen T.A., Bak A.A.A., Stolk R.P., et al. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. J Hypertens. 16:1990;689-696.
65. Agabiti-Rosei E., Zulli R., Muisean M.L., et al. Reduction of cardiovascular structural changes by nifedipine-GITS in essential hypertensive patients. Blood Press. 7:1998;160-169.
66. Nalbantgil I., Önder R., Killiçcioglu B., et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press. 5:1996;285-291.
67. Thürmann P.A., Stephens N., Heagerty A.M., et al. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Hypertension. 28:1996;450-456.
68. Horn H.J.H., Detmar K., Pittrow D.B., et al. Impact of a low-dose reserpine/thiazide combination on left ventricular hypertrophy assessed with magnetic resonance tomography and echo-cardiography. Clin Drug Invest. 14:1997;109-116.
69. Lombardo M., Zaini G., Pastori F., et al. Left ventricular mass and function before and after antihypertensive treatment. J Hypertens. 1:1983;215-219.
70. Cheung B.M.Y., Lan C.P. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Clin Pharmacol. 47:1999;179-187.
71. Shimamoto H., Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension. 28:1996;457-463.
72. Rizzoni D., Muiesan M.L., Porteri E., et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens. 15:1997;197-204.
73. Matsuzaki K., Mukai M., Sumimoto T., et al. Effects of ACE-inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. Hypertens Res. 20:1997;7-10.
74. Cuspidi C., Lonati L., Sampieri L., et al. Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Press. 7:1998;75-79.
75. 1)-receptor antagonist, on left ventricular mass and haemo-dynamics in patients with essential hypertension. Cardiovasc Drugs Ther. 12:1998;469-474.
76. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet. 349:1997;1743-1744.
77. Devereux R.B. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation. 95:1997;1983-1985.
78. Gottdiener J.S., Reda D.J., Massie B.M., et al. Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation. 95:1997;2007-2014.
79. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double blind studies. J Am Med Assoc. 275:1996;1507-1513.
80. Unger T., Cuhman J., Gohlke P. Angiotensin II-receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens. 16:(suppl.7):1998;S3-S9.